Lucid Diagnostics Inc. (LUCD)

Market Cap	43.30M
Revenue (ttm)	4.19M
Net Income (ttm)	-52.31M
Shares Out	55.45M
EPS (ttm)	-1.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	372,735
Open	0.790
Previous Close	0.771
Day's Range	0.780 - 0.800
52-Week Range	0.630 - 1.580
Beta	1.42
Analysts	Strong Buy
Price Target	3.63 (+364.79%)
Earnings Date	Nov 13, 2024

About LUCD

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in a...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 14, 2021
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: LUCD
• Website: https://www.luciddx.com

Financial Performance

In 2023, Lucid Diagnostics's revenue was $2.43 million, an increase of 544.03% compared to the previous year's $377,000. Losses were -$52.67 million, -6.24% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for LUCD stock is "Strong Buy." The 12-month stock price forecast is $3.63, which is an increase of 364.79% from the latest price.

Price Target

$3.63

(364.79% upside)

Analyst Consensus: Strong Buy